Literature DB >> 31239089

Post-procedural tricuspid regurgitation predicts long-term survival in patients undergoing percutaneous mitral valve repair.

Marwin Bannehr1, Ulrike Kahn2, Maki Okamoto2, Hidehiro Kaneko3, Valentin Hähnel2, Michael Neuß2, Anja Haase-Fielitz2, Christian Butter2.   

Abstract

BACKGROUND: Functional tricuspid regurgitation (TR) is frequently present in patients with severe mitral regurgitation and is associated with worse outcome. While percutaneous mitral valve repair (PMVR) is on the increase, the role of TR in those patients is unclear. This study aimed to compare pre- and post-procedural TR and investigated the impact of post-procedural TR and major clinical risk factors on long-term survival in patients undergoing PMVR.
METHODS: In this retrospective observational cohort study, data from 213 consecutive patients at a tertiary care center undergoing PMVR from 2010 to 2016 were analyzed. Two different groups, dichotomized according to the degree of TR (none/mild and moderate/severe) were compared. Multivariable analyses were performed assessing predictors for long-term survival adjusting for major risk factors.
RESULTS: Following PMVR TR was significantly reduced by at least 1 grade in 23.0% (p=0.001), while echocardiographic pulmonary pressure was decreased (TR Vmax 3.21±0.49m/s vs. 2.98±0.53m/s; p=<0.001). Patients with moderate or severe TR presented with worse New York Heart Association functional class and elevated N-terminal pro B-type natriuretic peptide levels compared to patients with none or mild TR. Median survival time was 1458 days. Proportional hazards model, adjusted for major risk factors, revealed post-procedural TR grade (HR 2.055, CI 1.317-3.206, p=0.02), severely impaired left ventricular function (HR 3.145, CI 1.199-8.250, p=0.020), and chronic kidney disease [glomerular filtration rate (GFR) 30-60ml/min HR 1.917, CI 1.109-3.314, p=0.020; GFR<30ml/min HR 3.969, CI 1.981-7.951, p<0.001] as independent predictors for long-term survival.
CONCLUSION: Post-procedural moderate and severe TR predicts worsened long-term survival in patients undergoing PMVR and is associated with adverse clinical outcome. Whether outcome might be improved by interventional reduction of post-procedural TR has to be investigated in the future.
Copyright © 2019 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MitraClip; N-terminal pro B-type natriuretic peptide; Percutaneous mitral valve repair; Survival; Tricuspid regurgitation

Year:  2019        PMID: 31239089     DOI: 10.1016/j.jjcc.2019.05.009

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  4 in total

1.  Invasive Hemodynamic Assessment and Procedural Success of Transcatheter Tricuspid Valve Repair-Important Factors for Right Ventricular Remodeling and Outcome.

Authors:  Varius Dannenberg; Matthias Koschutnik; Carolina Donà; Christian Nitsche; Katharina Mascherbauer; Gregor Heitzinger; Kseniya Halavina; Andreas A Kammerlander; Georg Spinka; Max-Paul Winter; Martin Andreas; Markus Mach; Matthias Schneider; Anna Bartunek; Philipp E Bartko; Christian Hengstenberg; Julia Mascherbauer; Georg Goliasch
Journal:  Front Cardiovasc Med       Date:  2022-06-02

2.  Right ventricular dysfunction and tricuspid regurgitation in functional mitral regurgitation.

Authors:  Vien T Truong; Tam N M Ngo; Jan Mazur; Hoai T M Nguyen; Thuy T M Pham; Cassady Palmer; Khanh N P Pham; Hoang T Phan; Kwan S Lee; Marwin Bannehr; Christian Butter; Takayuki Gyoten; Eugene S Chung
Journal:  ESC Heart Fail       Date:  2021-09-22

3.  Visualisation of the tricuspid valve using a new 3D echocardiographic scoring system.

Authors:  Tanja Kücken; Sarah Tamm; Anja Haase-Fielitz; Christoph Roland Edlinger; Michael Neuss; Marwin Bannehr; Christian Butter
Journal:  Open Heart       Date:  2020-09

4.  Progression of Chronic Kidney Disease and All-Cause Mortality in Patients with Tricuspid Regurgitation.

Authors:  Fabian Schipmann; Marwin Bannehr; Valentin Hähnel; Victoria Dworok; Jonathan Nübel; Christoph Edlinger; Michael Lichtenauer; Michael Haase; Michael Zänker; Christian Butter; Anja Haase-Fielitz
Journal:  Diseases       Date:  2022-03-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.